Integrated Approach to Biomarkers
Biomarkers Inform the Drug Development Process for Large and Small Molecule Drugs
Altasciences can extract meaningful data from measuring various intracellular, membrane-bound, and secreted circulating biomarkers to inform the development process.
We will help guide you towards a robust and fit-for-purpose biomarker solution involving veteran scientists, toxicologists and clinical pharmacologists to develop a comprehensive preclinical to clinical plan to maximize the translation of results from one phase to the next.
Expertise working with:
| Experience with the following studies:
|
You may also be interested in the following:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Top 5 Ways Liquid-Filled Capsules Accelerate Your Drug Development
Advantage of Liquid-Filled Capsules in Drug Development
Choosing the right dosage form for your API can be the key to accelerating your drug development timeline.
Liquid-filled, hard-shell capsules offer countless benefits over tablets and other solid oral dosage forms, in all phases of drug development ― especially for highly potent or challenging APIs.
View the infographic to learn more!
Have questions? Speak with one of our experts.
You may also be interested in:
- Webpage: Full Range of Manufacturing and Analytical Services
- Video: Quick Chat on Liquid-Filled Capsules with Ben Reed, General Manager, CDMO
- Webinar: The Development of Nanosuspension Formulations for Poorly Soluble Drugs
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Altasciences Receives 2022 CRO Leadership Award in Five Categories
Laval, Quebec, May 30, 2022 – Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science Leader.
Each year, Clinical Leader and Life Science Leader team up with ISR Reports to determine award recipients by assessing 50 CROs on more than 20 performance metrics in ISR’s annual Quality Benchmarking survey. This year, Altasciences received awards in the following categories: Capabilities, Compatibility, Expertise, Quality, and Reliability.
“Selecting the right CRO can make or break your project,” says Ed Miseta, Chief Editor for Clinical Leader. “It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients.”
Altasciences recognizes the importance of consistently exceeding the standards for excellence set by others in the industry, as well as their own. For more than 10 years, Altasciences has been transforming the traditional outsourcing paradigm, building a one-stop outsourcing solution that simplifies and accelerates the early phase drug development process for our partners. To that end, Altasciences is proud to have exceeded the expectations of small to large pharmaceutical companies, and will use the awards as further motivation to support educated, faster, integrated, and more complete early drug development decisions for their partners.
“To be recognized by the industry is not only an honor but a testament to the expertise of our people and the utmost care they show for both our partners and for those who seek the therapies we help develop,” says Chris Perkin, CEO at Altasciences. “To be acknowledged is a point of pride for our company, yes — but more importantly, it serves as a reminder that the more we build on our Capabilities, Compatibility, Expertise, Quality, and Reliability, the more our solutions can help our clients transform lives around the world.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
CONTACT:
Julie-Ann Cabana
Altasciences
514 601-9763
jcabana@altasciences.com
Moving in Unison with YOUR Projects in Mind
Three Strategically Located Preclinical Sites
Our three preclinical sites work in unison with our clinical, bioanalytical and manufacturing sites to offer an integrated drug development solution from lead candidate selection to clinical proof of concept. We offer a full range of in vivo non-GLP and GLP preclinical studies in both rodent and non-rodent species to thoroughly assess the safety of your molecules.
Our purpose-built:
- 550,000 sq.-ft.
- 260 custom-designed animal rooms, including North-American and European housing
- Capacity to house 3,320 NHPs, 965 canines, 920 swine, 27,320 rodents, 2,480 rabbits
- Barrier facilities for small animals
- Archive facility and services on site
- Laboratory services on site
You may also be interested in the following:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Real-World Insights from Biopharma Exec Survey — Selecting the Right CRO
One-Stop Solution for Meeting Your Needs in Outsourcing Drug Development
Altasciences recently conducted a survey to understand the challenges biopharmaceutical companies face when outsourcing their early phase drug development programs. Over 143 executives shared the important factors that guide them in the selection of a CRO partner.
Their candid testimonials are shared in this playbook, including:
- The significant challenges encountered when conducting preclinical and Phase I studies
- The unique difficulties of transitioning from preclinical to first-in-human studies
- The specific capabilities and expertise executives look for in their CRO partners
- The novel drug development solution approach for addressing the challenges encountered
Download your copy today.
Let us help! Speak with our experts today.
You may also be interested in the following:
Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
The Impact of Social Factors on Drug Development
Drug development exists within the context of interrelated social factors that impact its norms and practices.
Leading Your CTAs with Confidence
Quick Chat with Roland Jbeily, Regulatory Affairs Manager
Altasciences’ Regulatory Affairs team has significant expertise with regulatory bodies in both the U.S. and Canada. In this interview, Roland Jbeily discusses how our Canadian operations works as a bridge between sponsors and Health Canada providing strategic guidance to colleagues and sponsors to help advance drug development with speed and ease.
Watch the full interview and get through the CTA process with confidence:
You may also be interested in the following:
- Integrated Research Services
- Webinar — Discovering the Many Advantages of Conducting Early Phase Clinical Trials in North America
- The Altascientist — Planning Your First-in-Human Trial
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Seamless Bioanalytical Transition from Preclinical to Clinical, and Beyond
Seamless Bioanalytical Transition
Altasciences’ scientists move in unison with you, collaboratively, accurately, and efficiently, from preclinical to clinical, and beyond. Our team of over 260 bioanalytical scientific veterans is strategically located across North America, and has experience with a wide spectrum of biological matrices in both animal and humans.
Driven by your assay requirements, our program support includes LC-MS/MS, LBA OR HYBRID LBA/LC-MS/MS ASSAY platforms for:
|
|
Have 5 minutes? You may also be interested in the following:
- Assay List — Over 685 Assays covering 650 Molecules
- The Altascientist — Validation of Immunogenicity Assays
- Webinar — Development of a Cell-Based Assay for Dual Purposes: to Support Drug Potency and Immunogenicity Characterization
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
How Novel Data-Driven Treatments Are Improving Patient Care
PODCAST — How Novel Data-Driven Treatments Are Improving Patient Care
Special guest Dr. Michael Winlo, Managing Director at Emyria, joins us for a very insightful conversation about their unique programs and new patient care models. Emyria is a biotech company that brings together patients, clinicians, researchers, and medical innovators to develop data-driven, novel treatments for patients in need, including cannibidiol formulations.
Have questions? Speak with one of our experts.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.